TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05518448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone - beta-hydroxybutyrate (β-OHB)
Description: Ketone - beta-hydroxybutyrate (β-OHB)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ketone - beta-hydroxybutyrate (β-OHB)
Description: Ketone - beta-hydroxybutyrate (β-OHB)
Study: NCT05342207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic plantar fascia release in cases of chronic resistant plantar fasciopathy
Description: A medial portal will be developed 1cm away from the plantar skin along a vertical line passing through the posterior border of the medial malleolus with the foot in neutral position. A 5 mm cannula will be then introduced through the lateral portal over the trocar. Irrigation fluid will be then connected. A 30-degree 4.0 mm endoscope will be inserted inside the cannula. A 4.5 motorized incisor blade will be then used to debride the subcutaneous tissue until full visualization of the shiny fibers of the plantar fascia will be possible. A needle was inserted vertically through the heel skin to act as a land mark for the middle of the plantar fascia. A scalpel blade will then introduced through the medial portal to divide the full thickness of the medial half of the plantar fascia into two leaflets under direct visualization . The posterior leaflet will be then totally debrided using a motorized incisor blade . The tunnel will then be irrigated and stitches will be done.
Study: NCT05473819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Local Anesthesia
Description: Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe \[Tyco Healthcare, tyco.com\] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Unbuffered Local Anesthesia
Description: The control group will receive the unbuffered conventional anaesthetic solution
Study: NCT04606927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natriuresis
Description: Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.
Study: NCT05717582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apalutamide
Description: Patients receive apalutamide 240mg,qd,po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: Patients receive systemic ADT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive radical prostatectomy with/without pelvic lymph node dissection
Description: Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: metastasis-directed therapy with radiation
Description: Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.
Study: NCT04844125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: SHR-1209

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1209 Placebo
Description: SHR-1209 Placebo
Study: NCT06091904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
Study: NCT06019936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT2004 Capsule
Description: The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT2004 Capsule Placebo
Description: The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
Study: NCT06490991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 tablets；HRS-5965 capsules
Description: Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 tablets；HRS-5965 capsules
Description: Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules
Study: NCT06326632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant-load Aerobic Exercise
Description: The CL-AE group received a 12-week aerobic training, three times in addition to the respiratory re-training. the program included a moderate-intensity aerobic training program, with an intensity set at 65% of the maximum age-predicted heart rate for 45 minutes. The training intensity and duration were maintained at the same level throughout the program. The CL-AE program included a warm-up for 5 minutes and a cool-down for 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Aerobic exercise
Description: The G-AE group received a 12-week intensity- and duration-graded aerobic training, three times in addition to the respiratory re-training. The G-AE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The G-AE program also included a warm-up for 5 minutes and a cool-down for 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Re-training
Description: The respiratory re-training lasted for 30 minutes per session and was repeated three times a week for 12 consecutive weeks. The program consisted of diaphragmatic breathing exercises, breath-hold, and breathing control exercises, pursed lip breathing, respiratory muscle strengthening, postural correction exercises, and relaxation techniques.
Study: NCT05289349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (2 mg/kg) for induction of anesthesia , and ( 6 mg/kg/h) for maintenance of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane 1.0-1.5 minimum alveolar concentration (MAC)
Study: NCT04123314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
Study: NCT05136404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study: NCT06383117

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: 2 capsules containing 600 mg of calcium carbonate each

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: 2 capsules containing 600 mg of calcium carbonate each

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: 2 capsules containing methylcellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: 2 capsules containing methylcellulose
Study: NCT06050109

Intervention type: DRUG
Intervention: OFS continues to use group after 5 years use
Description: Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemical detection of HR status
Description: Enrolled patients must be HR-positive premenopausal breast cancer patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemical detection of HR status
Description: Enrolled patients must be HR-positive premenopausal breast cancer patients
Study: NCT03762291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD908ssb-TXSVN
Description: TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin.
Study: NCT05920746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy with magnetotherapy
Description: Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 10-20 Hz, type of impulse: bipolar, rectangular pulse
Study: NCT05101486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.PreF-based Vaccine
Description: Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.PreF-based Vaccine
Description: Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.PreF-based Vaccine
Description: Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.
Study: NCT06091904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
Study: NCT06469177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Coach App
Description: Pain Coach App is a mobile application that offers patients undergoing shoulder, hip and knee arthroplasty surgery preoperative educational tools and questionnaires to provide patient specific details to their surgeons for prescribing purposes as well as post operative pain assessment and medication reminders/tracking, problem troubleshooting and a resource library for further pain management tools and education.
Study: NCT06331858

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hip device-assisted concentric abductor strengthening (HDACAS)
Description: All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: knee device-assisted concentric flexor-extensor strengthening (KDACFES)
Description: All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: knee device-assisted concentric flexor-extensor strengthening (KDACFES)
Description: All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
Study: NCT05086718

Intervention type: OTHER
Group type: OTHER
Intervention: Endoscopic ear surgery
Description: Endoscopic approach without posterior meatal flap elevation will be employed in the ear with dry chronic suppurative otitis media. Tympanoplasty utilizing composite cartilage-fascia graft will be performed. After three months of time period successful outcome will be taken as closure of air bone gap on pure tone audiometry.
Study: NCT05590156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Description: Conventional treatment for the upper extremity will be applied according to the patient's individual needs. A physiotherapist will apply this method in the clinic for 60 minutes. The duration of treatment is 60x3x8 minutes/day/week. Other methods will be applied in addition to the conventional treatment program.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Description: Conventional treatment for the upper extremity will be applied according to the patient's individual needs. A physiotherapist will apply this method in the clinic for 60 minutes. The duration of treatment is 60x3x8 minutes/day/week. Other methods will be applied in addition to the conventional treatment program.
Study: NCT04817150

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral mesh rectopexy
Description: Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy
Description: Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore
Study: NCT05472493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [18-F]CETO
Description: PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, \~3 mm). CETO (\~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from \~0-90 minutes.
Study: NCT06488755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0718 injection
Description: Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks.~Duration of medication: 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SIM0718 injection of placebo
Description: Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks.~Duration of medication: 52 weeks
Study: NCT05090787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational mDCB00
Description: Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control DCB00
Description: Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes
Study: NCT05722197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Response Planning and Lethal Means Safety Counseling
Description: Crisis Response Planning is an efficacious, one-session intervention that increases positive affect, decreases negative affect and psychiatric hospitalizations, and reduces suicide attempts by 76% among Servicemembers
Study: NCT05487144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning in a Virtual Environment (LIVE)
Description: Phase 1 of the study will be a one-time meeting, either remote or in-person to complete V.E. training and fill out questionnaires. Phase 2 of the study is the 8 week intervention implementation.Participants will access the V.E. community from their homes on a computer with broadband internet. During the first four weeks of the intervention, participants will be required to come into the V.E. at least once per week for at least one hour. For the last four weeks, V.E. participation is strongly encouraged, but not required. The content in the V.E. will focus on psychosocial health and stroke recovery, and the messaging in the VE will be updated bi-weekly to encourage retention and engagement. Group meetings led by the study PI, a psychologist, or another trained member of the research team at least once a week will be offered. During the intervention period, VE-specific data will be collected continuously. Phase 3, will include a survey and a focus group interview via online platform.
Study: NCT06037070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: PRF will be injected inside the hole that prepared to place dental implant
Study: NCT06370390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: swallowing function training
Description: The group rehabilitation program comprised daily 60-minute sessions, five times per week for a duration of 4 weeks.~The group rehabilitation program included: Rehabilitation oral and facial exercises, Game-based surface electromyographic biofeedback training, Participants experience sharing, Individual direct feeding training
Study: NCT06068517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure wound therapy
Description: After the completion of abdominal surgery and standardised skin closure with staples, ciNPWT will be applied, using a commercially available device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing
Description: After the completion of abdominal surgery and standardised skin closure with staples, standard dressings will be applied.
Study: NCT05733780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolectin-M
Description: Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolectin-M
Description: Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolectin-M
Description: Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
Study: NCT05941286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM system with both glucose predictive alerts and threshold alerts on
Description: the cloud-based real-time continuous glucose monitoring and management system with both glucose predictive alerts and threshold alerts on
Study: NCT06203171

Intervention type: OTHER
Intervention: Observational
Description: Routine laboratory parameters requested from patients; Direct lung Radiograph and Electrocardiography results were evaluated and preoperative consultations and recommendations requested from the patients were recorded. Type of anesthesia, operation performed, operation duration, intraoperative blood and fluid losses, intraoperative and postoperative complications that develop within the first 24 hours, additional problems that develop (pain, postoperative nausea and vomiting, hypothermia, change of consciousness, bleeding and unplanned transfer to the intensive care unit). postanesthesia recovery The length of stay in the room, length of hospital stay, and method of discharge were recorded. The effects of preoperative laboratory, imaging methods and required consultations on intraoperative and postoperative complications in the first 24 hours were evaluated.

Intervention type: OTHER
Intervention: Observational
Description: Routine laboratory parameters requested from patients; Direct lung Radiograph and Electrocardiography results were evaluated and preoperative consultations and recommendations requested from the patients were recorded. Type of anesthesia, operation performed, operation duration, intraoperative blood and fluid losses, intraoperative and postoperative complications that develop within the first 24 hours, additional problems that develop (pain, postoperative nausea and vomiting, hypothermia, change of consciousness, bleeding and unplanned transfer to the intensive care unit). postanesthesia recovery The length of stay in the room, length of hospital stay, and method of discharge were recorded. The effects of preoperative laboratory, imaging methods and required consultations on intraoperative and postoperative complications in the first 24 hours were evaluated.
Study: NCT04797078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal biopsy
Description: Transperineal free hand MRI-US fusion prostate biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal biopsy
Description: Transrectal MRI-US fusion prostate biopsy
Study: NCT05310838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for First Episode Psychosis
Description: Sessions will be offered weekly and dyads can complete the intervention during a 6-month period to accommodate competing demands encountered by the population.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Given this condition, patients may also receive individual rehabilitation and/or group psychosocial interventions as part of typical clinic care.
Study: NCT05812469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Awareness Intervention
Description: effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Being Healthy Education
Description: This training included trainings on Healthy Nutrition, Sexually Transmitted Diseases, Importance of Physical Activity and Personal Hygiene prepared by the researcher in the form of presentations for the patients in the control group.
Study: NCT06134622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis plus tirofiban
Description: Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous thrombolysis plus placebo
Description: placebo (saline)
Study: NCT04103983

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sensory retraining device
Description: All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.